Deals

Oxygen Biotherapeutics Closes $52M CMPO at 10% Discount via Ladenburg, MTS Health

By |

Oxygen Biotherapeutics Inc. (OXBT) announced that it has raised $51,999,998 in a CMPO/Overnight transaction. The common stock was sold at $5.60 per share, an approximate 10% discount to the market price ($6.21) of OXBT at deal announcement. Ladenburg Thalmann & Co., Inc. and MTS Health Partners acted as underwriters on the transaction. Underwriter counsel was Ellenoff Grossman & Schole LLP and issuer counsel was Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, LLP. Note this Placement is subject to customary closing conditions and is expected to close by 03/21/2014.

Deals

pSivida Raises $7M in RDO at 7% Discount from RA Capital

By |

pSivida Corporation (PSDV) announced that it has raised $6,987,000 in a Registered Direct transaction. The common stock was sold at $4.11 per share, an approximate 7% discount to the market price ($4.42) of PSDV at deal announcement. Northland Securities acted as the exclusive agent on the transaction. The investor was RA Capital Management. The transaction is expected to close on March 18, 2014.

Deals

Anavex Life Sciences Raises $10M in Conv Debt Deal at 33% Discount via Maxim

By |

Anavex Life Sciences Corporation (AVXL) announced that it has raised $10,000,000 in a Convertible Debentures transaction. The fixed conversion price of the Convertible Debentures is $0.30 per share, an approximate 33.33% discount to the market price ($0.45) of AVXL at deal announcement. A series of 33,300,000 60-Month Warrants with an exercise price of $0.30 per share (33.33% discount) were issued to the investors in this transaction. An additional series of 33,300,000 60-Month Warrants with an exercise price of $0.42 per share (6.677% discount) were issued to the investors in this transaction. Maxim Group LLC acted as the exclusive agent on the transaction.

Deals

Omeros Closes $35M CMPO at 7% Discount via Cowen-led Syndicate

By |

Omeros Corporation (OMER) announced that it has raised $35,000,009 in a CMPO/Overnight transaction. The common stock was sold at $11.50 per share, an approximate 7% discount to the market price ($12.30) of OMER at deal announcement. Cowen and Company acted as the Sole Book-Runner, Wedbush PacGrow Life Sciences acted as Co-Lead Manager with Needham & Company, Maxim Group, WBB Securities, and MLV & Co. LLC acting as Co-Managers on the transaction. The offering is expected to close on or about March 19, 2014, subject to the satisfaction of customary closing conditions.